US Broker Ratings

MBX Biosciences, Inc. (MBX) Stock Analysis: Unveiling a 231% Potential Upside in Biotech Innovation

For investors with an eye on the biotechnology sector, MBX Biosciences, Inc. (MBX) offers a compelling narrative marked by innovation and substantial potential upside. This clinical-stage biopharmaceutical company is at..

Personalis, Inc. (PSNL) Stock Analysis: Navigating Potential Upside Amidst a Volatile Market

Personalis, Inc. (NASDAQ: PSNL), a leading player in the diagnostics and research sector, is catching the attention of investors with its potential upside of 9.89%. Specializing in advanced cancer genomic..

Arvinas, Inc. (ARVN) Stock Analysis: Exploring the Promising 148% Potential Upside

Arvinas, Inc. (NASDAQ: ARVN) stands as a compelling prospect in the biotechnology sector, driven by its innovative approach to targeting disease-causing proteins. As a clinical-stage company, Arvinas is at the..

COMPASS Pathways Plc (CMPS): Analyst Consensus Shows Nearly 500% Upside Potential

COMPASS Pathways Plc (NASDAQ: CMPS), a pioneering biotechnology firm, is at the forefront of developing innovative mental health treatments. With its operations spanning the United Kingdom and the United States,..

Claritev Corporation (CTEV) Stock Analysis: Navigating A -19.30% Potential Downside Amidst Healthcare Innovations

Claritev Corporation (NYSE: CTEV) stands out in the health information services sector with its innovative approach to data analytics and technology-enabled cost management. Headquartered in New York, this company has..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Promising Biotech with 85.87% Upside Potential

Enliven Therapeutics, Inc. (NASDAQ: ELVN), a clinical-stage biopharmaceutical company, offers a captivating opportunity for investors looking to tap into the burgeoning biotechnology sector. With a market capitalization of $1.27 billion..

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis: A Promising 82.42% Upside in Neurodegenerative Therapy

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a burgeoning player in the biotechnology sector, has captured the attention of investors with its focus on innovative treatments for neurodegenerative diseases. As a clinical-stage..

Orthofix Medical Inc. (OFIX) Stock Analysis: Unpacking a Potential 101.99% Upside

Orthofix Medical Inc. (NASDAQ: OFIX) presents a compelling case for investors seeking opportunities in the healthcare sector, particularly within the medical devices industry. With a market capitalization of $432.56 million,..

Precigen, Inc. (PGEN) Stock Analysis: Unlocking a 328% Upside Potential for Investors

Investors with an eye for biotechnology opportunities may find Precigen, Inc. (NASDAQ: PGEN) an intriguing prospect. With a market cap of $422.11 million, Precigen is positioned within the healthcare sector,..

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Exploring a 79% Potential Upside for Investors

Treace Medical Concepts, Inc. (NASDAQ: TMCI) is a noteworthy player in the healthcare sector, specifically in the medical devices industry. Headquartered in Ponte Vedra, Florida, Treace Medical is renowned for..

Savara, Inc. (SVRA) Stock Analysis: Exploring a 219% Potential Upside in the Biotechnology Sector

Savara, Inc. (NASDAQ: SVRA) is a biopharmaceutical company that has garnered substantial attention in the healthcare sector, particularly within the biotechnology industry. With a focus on rare respiratory diseases, Savara’s..

Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a Potential 81.72% Upside in the Healthcare Sector

Castle Biosciences, Inc. (NASDAQ: CSTL), a prominent player in the Healthcare sector, is making waves with its innovative diagnostic solutions for dermatologic cancers and mental health conditions. Headquartered in Friendswood,..

PureTech Health plc (PRTC) Stock Analysis: A Promising Biotech with Nearly 200% Upside Potential

In the dynamic world of biotechnology, PureTech Health plc (NASDAQ: PRTC) stands out not just for its innovative approach to healthcare solutions but also for its compelling investment potential. With..

Theravance Biopharma, Inc. (TBPH) Investor Outlook: Exploring a Potential 60% Upside

Theravance Biopharma, Inc. (NASDAQ: TBPH) is drawing investor attention with a promising potential upside of over 60%, according to the latest analyst ratings. As a key player in the biotechnology..

Sionna Therapeutics, Inc. (SION) Stock Analysis: A Potential 159% Upside in the Biotech Sector

Sionna Therapeutics, Inc. (SION), a dynamic player in the biotechnology sector, is drawing significant attention from investors with a remarkable potential upside of 159.61%. Headquartered in Waltham, Massachusetts, Sionna is..

Stoke Therapeutics, Inc. (STOK) Investor Outlook: Exploring an 88.98% Potential Upside in the Biotech Sector

Stoke Therapeutics, Inc. (NASDAQ: STOK) is emerging as a notable player within the biotechnology sector, offering a compelling investment opportunity with a potential upside of 88.98%. The company, headquartered in..

Sage Therapeutics, Inc. (SAGE) Stock Analysis: Navigating a Biotech with 78% Revenue Growth Amid Volatility

Sage Therapeutics, Inc. (NASDAQ: SAGE), a prominent player in the biotechnology sector, has captured investor interest with its strategic focus on brain health medicines. With a market cap of $581.13..

Cross Country Healthcare, Inc. (CCRN) Stock Analysis: Exploring a 37.93% Upside Potential in Medical Staffing

Cross Country Healthcare, Inc. (NASDAQ: CCRN) stands as a prominent player in the healthcare staffing industry, providing essential talent management services across the United States. With its headquarters in Boca..

Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A 216% Potential Upside Beckons Investors

Zenas BioPharma, Inc. (NASDAQ: ZBIO), a pioneering force within the healthcare sector, specifically the biotechnology industry, is capturing significant attention from the investment community. With its market cap standing at..

Valneva SE (VALN) Stock Analysis: Exploring a 132% Potential Upside in the Biotech Sector

For investors with an appetite for high-risk and high-reward opportunities, Valneva SE (NASDAQ: VALN) presents an intriguing proposition in the biotechnology sector. Based in Saint-Herblain, France, Valneva is a specialty..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds